Description
Clonality: Polyclonal
Host: Rabbit
Purification: Serum
Reactivity: Human, Mouse, Rat
CARD HyperOva - the super superovulation reagent
CARD HyperOva® (Japanese Patent No. 5927588) and CARD HyperOva® FD are superovulation reagents that induce ovulation at higher efficiency than conventional methods (PMSG-hCG) yielding 3-4 times more oocytes on average with C57BL/6J mice. They are also effective with other strains. Moreover, further gains in efficiency can be realized by using CARD Medium during the IVF procedure.
Why Use CARD HyperOva®?
Reduce Animal Use (contribution to the 3Rs of animal welfare - "Replacement, Reduction, Refinement"
Using CARD HyperOva® can reduce the number of oocyte donor mice by a factor of 1/3-1/4.
Optimization of Genetically Modified mouse Creation and Preservation
More ova from less mice usin CARD HyperOva® facilitates in vitro fertilization and embryo transfer.
Application to Valuable Genetically modified Mice
More ova from less mice using CARD HyperOva® on your valuable modified strains enables the large-scale preparation of embryos.
Composition
Anti-inhibin antibody.
Purified equine villus chorionic gonadotropin (eCG).
HyperOva Performance in Various Mouse Strains | |||||||
|---|---|---|---|---|---|---|---|
| * 7.5 IU of CARD HyperOva® or PMSG was injected to four weeks old female mice, then 7.5 IU of hCG was administered 48 hours later. Thereafter all ova obtained 17 hours after hCG injection were collected. | |||||||
| No. | Strain | Injection | Number of Oocyte Donors | Number of Inseminated Oocytes | Average Number of Ovulated Oocytes/Female | No. of Fertilized eggs | Fertilization Rate (%) |
| 1 | C57BL/6J | eCG | 10 | 277 | 27.7±5.4 | 267 | 96.4±3.2 |
| HyperOva | 10 | 1072 | 107.2±22.7 | 963 | 89.8±3.7 | ||
| 2 | BALB/c ByJ | eCG | 10 | 293 | 29.3±8.9 | 213 | 73.4±11.3 |
| HyperOva | 10 | 903 | 90.3±14.5 | 680 | 76.4±9.0 | ||
| 3 | C3H/HeJ | eCG | 10 | 286 | 28.6±8.4 | 251 | 87.8±22.6 |
| HyperOva | 10 | 520 | 52.0±18.1 | 446 | 85.8±15.5 | ||
| 4 | DBA/2J | eCG | 10 | 225 | 22.5±7.8 | 194 | 86.2±11.0 |
| HyperOva | 10 | 688 | 68.8±13.6 | 592 | 86.0±4.5 | ||
| 5 | FVB/NJ | eCG | 10 | 168 | 16.8±3.3 | 159 | 94.6±6.7 |
| HyperOva | 10 | 256 | 25.6±5.9 | 239 | 93.3±6.6 | ||
| 6 | CD1 | eCG | 10 | 202 | 20.2±8.0 | 146 | 72.3±16.0 |
| HyperOva | 10 | 337 | 33.7±9.9 | 269 | 79.8±19.6 | ||
HyperOva Frequently Asked Questions
Q: Is CARD Hyperova a mixture of eCG and inhibin antiserum?
A: Yes, it is mixed.
Q: Can you confirm the source of the horse gonadotropinâ¦recombinant or purified? If recombinant, from what organism? If purified, what is the country of horse origin?
A: The horse gonadotropin of HyperOva is purified, and the origin country of horse is Japan.
Q: What is the country of goat origin?
A: The goat is a male Saanen goat who was born and raised in Japan.
Q: Did the goat co-mingle with any other livestock?
A: No. Only with other goats.
Q: Is the antibody unprocessed goat serum?
A: The goat serum was 2 times diluted by physiological saline. The horse gonadotropin was dissolved in saline, too.
Q: For the goat anti-mouse inhibin antiserum, what is the source of the immunogen?
A: It is a synthetic peptide.
Q: I can see a clump/precipitate/sediment in the vial.
A: The clumps doesn't affect the effectiveness of CARD HyperOva. Please avoid the clumps and aspirate only other solution.
Q: Can the product in 1ml vials be refrozen once thawed if we only need to use 0.3mls from a vial, at a time?â
A: Once the 1ml vial is opened, please use it to administrate intraperitoneally all at once. The 0.1mL - 0.2 mL can be administered in mice.
Q: Is the product working after it was stored at 4°C for one week instead of -20°C ?
A: We cannot guarantee the quality under this storage condition. Since the HyperOva may have been inactivated, we cannot recommend you to use it.
Citation
Culture time of vitrified/warmed zygotes before microinjection affects the production efficiency of CRISPR-Cas9-mediated knock-in mice.
Nakagawa Y, Sakuma T, Nishimichi N, Yokosaki Y, Takeo T, Nakagata N, Yamamoto T.
Biol Open. 2017 May 15;6(5):706-713. PMID: 28396487
Genome Editing in Mouse Zygotes and Embryonic Stem Cells by Introducing SgRNA/Cas9 Expressing Plasmids.
Noda T, Oji A, Ikawa M
Methods Mol Biol. 2017;1630:67-80. PMID: 28643250
Ultra-superovulation for the CRISPR-Cas9-mediated production of gene-knockout, single-amino-acid-substituted, and floxed mice.
Nakagawa Y, Sakuma T, Nishimichi N, Yokosaki Y, Yanaka N, Takeo T, Nakagata N, Yamamoto T.
Biol Open. 2016 Aug 15;5(8):1142-8. PMID: 27387532
References
Immunotherapy using inhibin antiserum enhanced the efficacy of equine chorionic gonadotropin on superovulation in major inbred and outbred mice strains.
Takeo T, Nakagata N.
Theriogenology. 2016 Sep 15;86(5):1341-6. PMID: 27242176
Superovulation using the combined administration of inhibin antiserum and equine chorionic gonadotropin increases the number of ovulated oocytes in C57BL/6 female mice.
Takeo T, Nakagata N.
PLoS One. 2015 May 29;10(5):e0128330. PMID: 26024317
